Biosimilar Hearing Will Consider Whether 'Umbrella' Exclusivity Policy Warranted
US FDA asks for comments on whether the policy employed for small molecule generics also should apply to biosimilars.
US FDA asks for comments on whether the policy employed for small molecule generics also should apply to biosimilars.